I've seen comments on HN when this point was raised, that newer antbiotics are also held back for serious cases so sales turn out lower during the patented life of the drug, which provides a further disincentive for developing them.
It's also been pointed previously on HN out that vaccines are one-shot drugs that are still developed (indeed, my kids have had 6-in-1 and MMRV combination vaccines, which reduce the number of shots needed by kids-I don't know how that works out for drug companies, but I doubt it increases their volumes) .
It's also been pointed previously on HN out that vaccines are one-shot drugs that are still developed (indeed, my kids have had 6-in-1 and MMRV combination vaccines, which reduce the number of shots needed by kids-I don't know how that works out for drug companies, but I doubt it increases their volumes) .